Model PrecivityAD2 - Blood Test
The PrecivityAD2™ blood test is intended for patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia, who are undergoing evaluation for Alzheimer’s disease or other causes of cognitive decline. A multi-analyte clinical diagnostic tool developed by C2N Diagnostics, the PrecivityAD2™ blood test aids healthcare providers in the detection of brain amyloid plaques, one of the neuropathological findings of Alzheimer’s disease. The test’s proprietary Amyloid Probability Score 2 (APS2) result, which incorporates p-tau217/np-tau217 Ratio and Aβ42/40 Ratio using an analytically and clinically validated algorithm, correlates more closely with brain amyloid pathology as determined by PET scan than to the individual biomarker measurements considered separately.1
Step 1
Healthcare provider orders the PrecivityAD2™ blood test and schedules a blood draw appointment
Step 2
Blood sample is sent to C2N’s laboratory for analysis
Step 3
Healthcare provider receives the PrecivityAD2™ report and discusses the results with the patient
Plasma from the patient’s blood sample is analyzed for amyloid beta and tau protein forms that are known biomarkers for brain amyloid pathology. Precise analyte concentrations are measured using state-of-the-art technologies, then calculated as ratios: Aβ42/40 Ratio and p-tau217/np-tau217 Ratio. The Ratios are incorporated into a clinically validated algorithm to determine the Amyloid Probability Score 2 (or APS2).
PrecivityAD2™ blood test results must be interpreted in the context of other patient information.
Positive
A positive PrecivityAD™ APS2 result is consistent with a positive amyloid PET scan and a high likelihood of the presence of brain amyloid plaques, one of the neuropathological findings of Alzheimer’s disease1. The presence of amyloid plaques alone does not establish a diagnosis of AD.
Negative
A negative PrecivityAD2™ APS2 result is consistent with a negative amyloid PET scan; it reflects a low likelihood of brain amyloid plaques and therefore is not consistent with a neuropathological diagnosis of Alzheimer’s disease1.
All reports provide an APS2 score, Aβ42/40 Ratio, and p-tau217 Ratio along with the positive or negative result.